FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319079877> ?p ?o ?g. }

• W4319079877 endingPage "175883592311518" @default.
• W4319079877 startingPage "175883592311518" @default.
• W4319079877 abstract "Background: Abemaciclib is the first and only cyclin-dependent kinases 4 and 6 inhibitor approved for adjuvant treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), node-positive, and high-risk early breast cancer (EBC), with indications varying by geography. Premenopausal patients with HR+, HER2− tumors may have different tumor biology and treatment response compared to postmenopausal patients. Objectives: We describe the efficacy and safety of abemaciclib plus endocrine therapy (ET) for the large subgroup of premenopausal patients with HR+, HER2− EBC in monarchE. Design: Randomized patients (1:1) received adjuvant ET with or without abemaciclib for 2 years plus at least 3 additional years of ET as clinically indicated. Methods: Patients were stratified by menopausal status (premenopausal versus postmenopausal) at diagnosis. Standard ET (tamoxifen or aromatase inhibitor) with or without gonadotropin-releasing hormone agonist was determined by physician’s choice. Invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) by menopausal status were assessed at data cutoff on 1 April 2021 (median follow-up of 27 months). Results: Among randomized patients, 2451 (43.5%) were premenopausal and 3181 (56.4%) were postmenopausal. The choice of ET for premenopausal patients varied considerably between countries. Treatment benefit was consistent across menopausal status, with a numerically greater effect size in premenopausal patients. For premenopausal patients, abemaciclib with ET resulted in a 42.2% and 40.3% reduction in the risk of developing IDFS and DRFS events, respectively. Absolute improvement at 3 years was 5.7% for IDFS and 4.4% for DRFS rates. Safety profile for premenopausal patients was consistent with the overall safety population. Conclusion: Abemaciclib with ET demonstrated clinically meaningful treatment benefit for IDFS and DRFS versus ET alone regardless of menopausal status and first ET, with a numerically greater benefit in the premenopausal compared to the postmenopausal population. Safety data in premenopausal patients are consistent with the overall safety profile of abemaciclib." @default.
• W4319079877 created "2023-02-04" @default.
• W4319079877 creator A5001211980 @default.
• W4319079877 creator A5001838875 @default.
• W4319079877 creator A5004846711 @default.
• W4319079877 creator A5007579054 @default.
• W4319079877 creator A5008665323 @default.
• W4319079877 creator A5011644667 @default.
• W4319079877 creator A5024024937 @default.
• W4319079877 creator A5024569256 @default.
• W4319079877 creator A5027231412 @default.
• W4319079877 creator A5031915637 @default.
• W4319079877 creator A5032340945 @default.
• W4319079877 creator A5034863656 @default.
• W4319079877 creator A5044867822 @default.
• W4319079877 creator A5048281465 @default.
• W4319079877 creator A5049683930 @default.
• W4319079877 creator A5059941445 @default.
• W4319079877 creator A5067146231 @default.
• W4319079877 creator A5071404457 @default.
• W4319079877 date "2023-01-01" @default.
• W4319079877 modified "2023-10-16" @default.
• W4319079877 title "Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer" @default.
• W4319079877 cites W2118696602 @default.
• W4319079877 cites W2169649287 @default.
• W4319079877 cites W2505695170 @default.
• W4319079877 cites W2804413675 @default.
• W4319079877 cites W2806866264 @default.
• W4319079877 cites W2807638929 @default.
• W4319079877 cites W2922196630 @default.
• W4319079877 cites W2924159870 @default.
• W4319079877 cites W2946519987 @default.
• W4319079877 cites W3044605555 @default.
• W4319079877 cites W3116378180 @default.
• W4319079877 cites W3167364940 @default.
• W4319079877 cites W3206169364 @default.
• W4319079877 cites W4206349107 @default.
• W4319079877 doi "https://doi.org/10.1177/17588359231151840" @default.
• W4319079877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36756142" @default.
• W4319079877 hasPublicationYear "2023" @default.
• W4319079877 type Work @default.
• W4319079877 citedByCount "1" @default.
• W4319079877 countsByYear W43190798772023 @default.
• W4319079877 crossrefType "journal-article" @default.
• W4319079877 hasAuthorship W4319079877A5001211980 @default.
• W4319079877 hasAuthorship W4319079877A5001838875 @default.
• W4319079877 hasAuthorship W4319079877A5004846711 @default.
• W4319079877 hasAuthorship W4319079877A5007579054 @default.
• W4319079877 hasAuthorship W4319079877A5008665323 @default.
• W4319079877 hasAuthorship W4319079877A5011644667 @default.
• W4319079877 hasAuthorship W4319079877A5024024937 @default.
• W4319079877 hasAuthorship W4319079877A5024569256 @default.
• W4319079877 hasAuthorship W4319079877A5027231412 @default.
• W4319079877 hasAuthorship W4319079877A5031915637 @default.
• W4319079877 hasAuthorship W4319079877A5032340945 @default.
• W4319079877 hasAuthorship W4319079877A5034863656 @default.
• W4319079877 hasAuthorship W4319079877A5044867822 @default.
• W4319079877 hasAuthorship W4319079877A5048281465 @default.
• W4319079877 hasAuthorship W4319079877A5049683930 @default.
• W4319079877 hasAuthorship W4319079877A5059941445 @default.
• W4319079877 hasAuthorship W4319079877A5067146231 @default.
• W4319079877 hasAuthorship W4319079877A5071404457 @default.
• W4319079877 hasBestOaLocation W43190798771 @default.
• W4319079877 hasConcept C121608353 @default.
• W4319079877 hasConcept C126322002 @default.
• W4319079877 hasConcept C143998085 @default.
• W4319079877 hasConcept C2776215463 @default.
• W4319079877 hasConcept C2777176818 @default.
• W4319079877 hasConcept C2777863537 @default.
• W4319079877 hasConcept C2778812593 @default.
• W4319079877 hasConcept C29456083 @default.
• W4319079877 hasConcept C530470458 @default.
• W4319079877 hasConcept C71924100 @default.
• W4319079877 hasConceptScore W4319079877C121608353 @default.
• W4319079877 hasConceptScore W4319079877C126322002 @default.
• W4319079877 hasConceptScore W4319079877C143998085 @default.
• W4319079877 hasConceptScore W4319079877C2776215463 @default.
• W4319079877 hasConceptScore W4319079877C2777176818 @default.
• W4319079877 hasConceptScore W4319079877C2777863537 @default.
• W4319079877 hasConceptScore W4319079877C2778812593 @default.
• W4319079877 hasConceptScore W4319079877C29456083 @default.
• W4319079877 hasConceptScore W4319079877C530470458 @default.
• W4319079877 hasConceptScore W4319079877C71924100 @default.
• W4319079877 hasFunder F4320307758 @default.
• W4319079877 hasLocation W43190798771 @default.
• W4319079877 hasLocation W43190798772 @default.
• W4319079877 hasLocation W43190798773 @default.
• W4319079877 hasOpenAccess W4319079877 @default.
• W4319079877 hasPrimaryLocation W43190798771 @default.
• W4319079877 hasRelatedWork W1491737910 @default.
• W4319079877 hasRelatedWork W1966100371 @default.
• W4319079877 hasRelatedWork W1971410221 @default.
• W4319079877 hasRelatedWork W2007182497 @default.
• W4319079877 hasRelatedWork W2028465294 @default.
• W4319079877 hasRelatedWork W2040234260 @default.
• W4319079877 hasRelatedWork W2043253988 @default.
• W4319079877 hasRelatedWork W2090744251 @default.
• W4319079877 hasRelatedWork W2134586533 @default.

• next